URL: https://humoruniv.com/pds1338612 URL |
|
Ʈ1 |
![]() ƴ̷ |
ϴ... SGLT2 ž ƴ. 索߿ Ⱦ̰, 索Ӹ ƴ϶ 庴 Ǵ ִ . ü κ 索 ߱ ü ҿ . ȭ ϴ ε, ӽִ ȿ Ư ġ Ǵ . ϴ SGLT2 û ΰ ó ִµ, ū Ǵٺϱ 汤 Ųٴ° . ϱ ư Ȯϱ ... 鿡Դ 汤 ū ƴҼ ̷ ߵǴ ε鿡Դ 汤 ɰϰ ̱ ൵ ó ΰ ƴ. [25]
|
139 1 |
![]() ![]() ![]() ![]() |
2024-11-22 11:18 |
||||
Ʈ2 |
![]() ƶ |
ž ¥ ʹ ű [7]
|
74 2 |
![]() ![]() ![]() ![]() |
2024-11-22 10:42 |
||||
![]() |
û |
Ư ´
|
20 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
ƶ |
ž ¥ ʹ ű
|
742 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
|
|||||||||||
![]() |
![]() ķھ |
뼼 ¸
|
100 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() Ѿ |
ѱ̸ ġ սô
|
230 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ƶ |
߰ ƽó? ? äâ̿?
|
220 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ĶǴ |
ž : ŵ ŵ ϳ ƿ ŵ : ž : 缱 ϳ : ( 帳 缱 ġ϶ϸ )
|
20 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() õϸŭ |
ܿ!
|
20 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() վ |
ϳ
|
70 |
![]() ![]() ![]() |
2024-11-22 |
||||||
|
|||||||||||
![]() |
![]() dragonash2 |
ù ȴ
|
00 |
![]() ![]() ![]() |
2024-11-23 |
||||||
|
|||||||||||
![]() |
ģ |
鿡 ó̐ ᱹ ؾϴ±
|
10 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
̰ ߰ ۿ ü߰
|
10 |
![]() ![]() ![]() ![]() |
2024-11-22 |
|||||||
![]() |
o |
Ŀ = ִ ɼ Ƽ... Ӱ... Ѱ Ф
|
173 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
ƴѵ. ߸ ˰ֳ.
|
101 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
? ǻ.
|
121 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ÷ |
索 Դϴ. Ӵ ¾ƿ. sglt2 ε ϴ. ü ˵ ö ó游 ϴ.
|
51 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
' ɼ' Ʋȴٴ¸ε 索ȯں Ͻð ǰ? 索 ߿ϰ ÿ ü ߿ DZ ϳ 'ü ˵ ö ó游 ´' ƲԴϴ.
|
50 |
![]() ![]() ![]() |
2024-11-22 |
||||||
|
|||||||||||
![]() |
![]() ÷ |
sglt2 ʽϴ. 2 索 ߺʱ ü߰ ߿ϱ sglt2 ü߰Ҷ DZ ü Ȯ ̰ ó ° ̿. ȭ ϸ ó ϴ. ó sglt2 θ ó 쵵 ־. ̳ sglt2 忡 Ȯ ִ° ̱. ġ 뷮 ֽʴϴ. ߰ sglt2 ߴٰ ü߰ Ƽ ٽ ó Ҿ. 뷮 Ҷ ġ Ƽ 뷮 ״ ߾ϴ.
|
12 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
Դϴ. Ӵ ƲȽϴ. ̻Ѹ Ʈ . SGLT2 inhibitor metformin ξ Դϴ. ̱ ϰ ۿ . (ź) Կȯڿ Ű Դϴ ( ...). 索 ȽѺе óϴ ప 翡 忡 ɷ ٸ HbA1C 索ȿ ־ SGLT2 ϴ . SGLT2 inhibitor 索 ź ȯڵ 忡 ȴٴ ־. ̶ protective ̶ Ҹ .
|
250 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ̷°žƴϴٳ |
IgAԴ ?
|
00 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
÷ ƴϸ ۶߸ ʴ° ڽϴ. SGLT-2i Ѵٰ ϸ ʽϴ. ϸ . ? ̰ , 索 , 索 ݵǴ Ʈϱ. ΰ ű Ʈ? ƴ϶°ſ. ɿ 뷮 ϴ° 輳dz ʴ, Ȥ ɿ Ư ۿ ų ִ ϴ° ű Ʈ ־ ϴ ƴմϴ. Ȱ ؼ ȭҰ Ȯ 翬 ó ʿ䰡 翬 ƴѰ?
|
110 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
IgA... Ȥ ź Ͻô° ź̶ ϰ ǰ ... SGLT2i GLP1 ü.
|
10 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
索ȯڶ Ȱ ó° ƴϰ ǻ縶 ٸ ȯڸ ¥ ɹԴϴ. ... ̽ Ἥ... ̱ ž 索ϸ SGLT2i ƴϸ GLP-1 ü( 컩 迭)̱. Ѵ egfr recommendeḏ ϰ... . sulfonylurea thiazolidinediones迭 ôºе ־. 索 ѵΰ ƴϰ ۿ ٸ ̷ ó´ٰ ؼ Ȱ ƴϿ. DPP4i ... ȯ̽Ű ˰ ̻Ѹ Ʈ װ ǻ簡 ؾߵǴµ
|
80 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ̲ٴ³ ![]() |
|
90 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ž |
|
10 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
̰ ٷ θ û . ϴ Ե Ͻð. ̶ 忡 ӻ Ÿм ؼ ɰ ۿ ɼ ̾߱⿴ϴ. Ŀ´Ƽ ڱ SGLP-2 ڷ ʹ ö ش ǰ ̷ ƴѰ ϴ ǽɵ ֱ.
|
63 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
ʺ ǻ ֳ? Ѱ ũ Դϴٸ
|
61 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ƴϱװԾƴ϶ϱ |
е Ű澲 ð ִ° 弼.. ǻ簡 ãƺ ̻ ãƺ ̴ϴ.
|
120 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
纴 ̰ Դٰ 汤 Ǽ ô е ϴ. ؼ մϴ...
|
31 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
ٸ ϱ ο Ǵ ǻ ̴ϴ. ̷ ڷ ּ ϴ ƴ϶. ƴԿ;;
|
41 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
ų '' ٰ ͼ °ź. 10 ȵż ߿ ɰ ۿ ' ִ'? ɵ Ŀ ڴ ִ ɼ ٰ Ҹس . ó浵 ũ ? ܿ ϴ¸ ¼ Ϸ ãƺ ڳ. ̷ϱ ǻ簡 °.
|
102 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
Ҹ ? Ѿ̿? ũ İ? ۿ ǿ ȯڵ Ѿ Ѵ ? پڴ ?
|
121 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
ð ° 12 ƴµ ... ƿ. 忡 protectiveϴ ۿ µ ߿ 忡 Ͱ üִٶ Ͽ ϴ°... evidence based medicineε Ͻô° ׳ ݾƿ; Ѻ̽ŵ... Ŵٸ鼭 GLP1a Ͱ ...
|
120 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
ǵɷ ߴ ﻩ Ѿ⸸ ϱϴ°͵ ̷ ... ۿ ǿ »鿡 ãƺٰ? ʳ ϼ SGLT2i ɼ ٰ ˰ôº ̳ Ͻðڳ
|
90 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
ȣī//glp1a Ʈ ƴݾƿ;; Դٰ 12 ̶ ̶ ƿ ٰ Ǯ ü ϱ. 汤 Ÿ öͼ ô ̽ ϴ. ƿ ڸ ڱ ´ ǵ ƴϿ.
|
80 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
ʺ// ˾Ƽ ϰ ְ. ε ٰ Դٰ 汤 ö ſſ İ ô ϴ Ҹ. ʿ ǻ ߿ ο ϴ ڳ.
|
62 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
¼ װ 汤Ÿ APNȰ ǻ ִ ƽó. ٴ ¼ ѹ Ű ǰ ȣ鰩̳. ü 100% ϰ ִ ü ? 100% ˰ڳ. 翬 ۿ ۿ غ ̵ е ũ SGLT-2i ̾°ǵ ¼ ̽ åӰ پſ 索ȯڵ 鼭 Ͱ ִ ̶µ ̵ ó߳İ ϴ° غ? Evidence-based medicine ⺻ ȵŰ ũ ãƺٴ...
|
163 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
UTI ̶ ̿? SLGT2i ɿ ٴ ϳ ຸ. ڱ ̾߱⸦ Ͻô°? Դ° ݴ egfr 30 ۵... ¥ Ѥ
|
130 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
ƈ ʹ dzѵ? ȯڰ ǿ ĵ? Ե ϰ ; ebmŸµ ʿ ȯڴ standard ƴϿ case.
|
51 |
![]() ![]() ![]() |
2024-11-22 |
||||||
|
|||||||||||
![]() |
![]() ȣī |
ð ƴϰ Ǵ dz ϴ° EBM... Ȧ. ϳ.
|
151 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
⺻ ȵǾ־ ̷ ȵǾ ֳ... װź ȯڰ ȶĿ´ٰ? ¥ ǻ ϰ ±. ű, UTIȯڴ 'case'ϱ װź ִ ɼ ־ ȵȴٰ ص ȴ? case ϳ standardΰŸ ҸѰ ġ ó. ̷ '' ˸ŭ ƴϱ ⺻ ϴ°ű
|
130 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
20 |
![]() ![]() ![]() |
2024-11-22 |
|||||||
![]() |
![]() o |
EBM ߿ ? ȯڰ µ EBM 缭 ٰ ? ƴ Ʊ ̾߱ߴµ ʺ ǻ ģ̶ ? ڲ οµ? ̰ ¥. METAм ? ӻ ̽ װ Ÿ ִٰ ؾ EBM ó ? ̰ Ű ӻ ȯ 켱̶ ?
|
40 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
Ȥ UTI ̶ ô° ƴ?......;;
|
100 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
β. Ǵ ̰ ... Kidney function̶ UTI ٸ ֽðھ? UTI Ȱɸٰ . 幰ٰ .
|
60 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
̶ ? ƿ ⺻ ưó
|
10 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
, ϰ ְϰ ִµ, ٴ ¼ ѹ 'UTI'̽ 'SGLT-2i ϸ eGFR ũ ɼ ' Ҹ Ѱű, EBM ƴ϶ ⺻ ǰ赵 ڽź ǵƺ ϴ°ű, SGLT-2i UTI risk ϴ и ̳ UTI High risk group ִ ȯڵ UTI case SGLT-2i UTI High risk group̱ UTI ѹ ϰ 'SGLT-2i eGFR UTI risk ȵȴ ô' ϴ evidence standard out of standard practice ž ϱ.
|
110 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
幰. ٵ ȯڱ װ ٸ ȯڱ ؼ ٱ. ذ ?
|
30 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
״ϱ Kidney function ٴ ߴ UTI ɸٴ ̽ ָ 翬 ? ο ̻Ű Դٰ ϽDZ?
|
80 |
![]() ![]() ![]() |
2024-11-22 |
||||||
|
|||||||||||
![]() |
![]() ʺ |
Current UTI ִ SGLT-2i Ѵٰ Ѹ . UTI risk SGLT-2i Ⱦ SGLT-2i ̵ е Ѵٸ 翬 Ѵٰ ̰. ȯڵ ϰ ô տ ̳ غ ѱ 翡 ȯڱ ¼ ¼ ϴ ҸѰ ƴ϶ ̰. ó Ҹ ߱淡 ǵ Դ SGLT-2i eGFR Ʈٴ evidence ü 淡 װ ֽ ϰ UTI ⸸ ֱâ ϴ ڽ ƺñ ٶϴ.
|
90 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
, = egfr ڱ ؼس ġ ʴϴ?
|
00 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
¥ ϳ Ե Դٰ sglt2 δٰ Դٰ İ Ǽ ź ô е ? ̾߱⸦ ϰ ִٰ ̰
|
00 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
UTI ٰ ʽϴ ^^ Ǵ ǥ ƴ϶ θ ǥ Ͻô ̾ ̷ ǻ ϸ ȵǴ°ǵ... θζ ɿ SGLT-2i UTI risk ϱ ϳ? ƴ϶ ϰֳ. ̻ ƹ ǹ̰ ٴ° ˾Ҿߴµ
|
120 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
翡 ̽ û ߴٰ ϴ°Ͱ ̽ ϰ manageϴ° ˹ٳ ¦غ ƴ϶ 뺴 ϰ 츮Դϴ ϼ
|
90 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
̳ а ð, ںν ó.
|
00 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
Ͻô° ٵ ٰ ؿ. ¥ Ϸ ϴ° ƴϰ ľ ϴ 峭 . ź ϸ ȸԾ ִ°Ű ȴ ִ°Ű. ϴ Kidney function ٴ° ջ ϴ° function loss ƴ϶. UTI ɸ 1 foleyε 纴 ȯڵ Ǵ UTI ٸ ׳ ɾ ... SGLT2i Դ 索ȯڸ ȸԾ ܿ Ȯ ("索") high risk ȯڰ UTI ° ට ؾ...?
|
140 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ƴϱװԾƴ϶ϱ |
̰ ̷Ա ο ִ ڴµ ǻ缱 ο̴ ¥ ǻ糢 ° ƴ϶ ʻ о ȯ Ǯ ʰ ϴ ü Ѱ谡 ֽϴ. ȶϽð Ͻð ˰ڴµ κ ִٴ ô° ū װ ų ° Դϴ. ´ٴϱ? Ͻ.. ΰ ǽ ǻ翩 ǻݵ ݵ ˾Ƶϴ.
|
200 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
Ѱ ߴ ο͵ °ų ̷Ÿ ǻ ܿƳ? ںν Ϲε ƽǵ ˹ٶپ ǻ vs ܷ, , ȯڽ ǻ
|
100 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
Urinary tract obstruction ִ UTI ̽ε SGLT-2i UTI risk factor° Urinary tract obstruction ξ ӻ ߿ϰ ϸ ذ ־߸ ϴ UTI ߿ risk factor ó? 翬 ̽ ؼ ߴؾϴ° Ͱ ̰ź ? ̰ɺ θ ҰŸ ϶ Ͻô°̴ϴ
|
110 |
![]() ![]() ![]() |
2024-11-22 |
||||||
|
|||||||||||
![]() |
![]() o |
ε ȯ ϰ sglt2 ̼. ʺ ںν ˻غ.
|
12 |
![]() ![]() ![]() |
2024-11-22 |
||||||
|
|||||||||||
![]() |
![]() ƴϱװԾƴ϶ϱ |
̾߱⸦ ݴ ˾Ƶô ϴ ġ ͵ ƴϰ г ƴϸ ϸ Ѱ а ˰ְ Ǹ Դϴ. ǻ纸 索 ° ? ٴϱ? ǰ 1̴ ־.. ٵ ʾƵ ſ. Ѵٸ Ϸ ϰ ϸ ͳݿ ߱Ÿ ð Ʈ ʿ䰡 ֳ.. ..
|
100 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
ƴϱװ//ƴ װ װ ƴѵ... ȿ... ׳ ̶ ٲ̾?
|
21 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
^^ ȯڻ ϰ ִ ɼ ̶ ȯڻ¸ ϶ Ͻô Ҹ ִ ̶ 翬 ˾ƺ ȯڻ¸ ʰ ھƾ Ѵٴ Ѹ ϴ и ȯڻ ϰ Ҹ Դϴ.
|
50 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
ƺ ٰ ڱ ƴ ô . ׳ ϴ ...
|
10 |
![]() ![]() ![]() |
2024-11-22 |
||||||
|
|||||||||||
![]() |
![]() o |
ڻ//кλ ص ȴٰ ŵϰ ϸ ڿ ̾߱⸦ ̵ ⼳ DZ Դϴ.
|
24 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() CADENZA |
ǻ ϳ....索ƴѵ ð ̾Ʈ ó ȿξ?
|
00 |
![]() ![]() ![]() |
2024-11-22 |
||||||
|
|||||||||||
![]() |
![]() ȫ» |
ɽοФб ο
|
20 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() |
ο
|
90 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() Ʈġ |
̰ ̱?? ϴ ǻ Ѹ ٱ°ֱѵ
|
60 |
![]() ![]() ![]() |
2024-11-22 |
||||||
|
|||||||||||
![]() |
![]() ׳ |
ǻ缱 Ʋ ƴѵ Ϲݴߵ ϰ ٸ ߲ѵ ð
|
41 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ž |
ǿ Ϲǿ ǻ簡 ǰ Ϲ ǰ߿ ۿ ´ Ƴ...?
|
41 |
![]() ![]() ![]() |
2024-11-23 |
||||||
![]() |
![]() ȣī |
Cadenza/ 索 컩µ ſ. ̶ ɷ Ϸ翡 50 (200Cal) ðſ.
|
20 |
![]() ![]() ![]() |
2024-11-23 |
||||||
![]() |
![]() Adeline |
ڷ 컩 ¾Ƶdz ܴ
|
00 |
![]() ![]() ![]() |
2024-11-23 |
||||||
![]() |
![]() ȣī |
̱ ۳ 컩¿ ι. μ Ⱦµ ѱ ߳? ´ Ĵܰ ϼžؿ. Ѱ谡 ְ 컩µ ߿Ѱ Ȱ ٲٴ°ſ. մµ ѹ غ..?
|
00 |
![]() ![]() ![]() |
2024-11-23 |
||||||
![]() |
![]() pupapupa |
̰ ǿ ׳ ħ ߰ڴ ʹ..
|
60 |
![]() ![]() ![]() |
2024-11-23 |
||||||
![]() |
![]() Adeline |
亯 .. ̱ Ƽ ɾ ҰŰ 翬 ϴµ ø
|
00 |
![]() ![]() ![]() |
2024-11-23 |
||||||
![]() |
û |
̿ 컩°ſ 索ٰ̿ϴ
|
00 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ó |
´ Ŀ ȭӵ , ν
|
30 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() е |
SGLT2 GLP1 ȿ
|
00 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
ƿ¼Ƽ |
ġ ν ñ° ƴ϶ Һ ؼ ؼ ü 緮 ٴ°ǰ..
|
10 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
Ǹߴ |
̰ 䵵 ٺϱ 䵵 ؾ Ѵ. 索 ȯڵ ܿ ϰ ־ Ȱ.
|
20 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
ƴ̷ |
ϴ... SGLT2 ž ƴ. 索߿ Ⱦ̰, 索Ӹ ƴ϶ 庴 Ǵ ִ . ü κ 索 ߱ ü ҿ . ȭ ϴ ε, ӽִ ȿ Ư ġ Ǵ . ϴ SGLT2 û ΰ ó ִµ, ū Ǵٺϱ 汤 Ųٴ° . ϱ ư Ȯϱ ... 鿡Դ 汤 ū ƴҼ ̷ ߵǴ ε鿡Դ 汤 ɰϰ ̱ ൵ ó ΰ ƴ.
|
1391 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
UTI ɷ ̽ ƿ. Ͻô°ó ʾƿ. 索 ߿ ¥ ´µ ۿ ϳ dz... ̱ ϰ Ŭп UTI ̽ ѹ .
|
62 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
ȣī Ȥ ȯڰ ַ е ƴϽŰ? 亴 Ⱑ ٸϴ.
|
131 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
Inpatient ´ٴ° ü ǰ ٴ ̰. ̵ е » ƿ. ¥ 60+ /ƾ迭е ΰ 索 ִµ... ѱ ϳ? DZ
|
80 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
ƿ 60~80븸 ѱ 纴̶ ̱ Ŭϰ Ⱑ ٸ ϴ. Ư VIP ŵ̶ ؾϳ ٰ ôٰ Ż ̽ ƿ...
|
50 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
ϴµ Ժ ξ 索ȯڸ ôٰ Ҽ ־. ˼ ż ϴ¸ ŵ Ŭ ȵ. Inpatient . ICU endo ϴµ ǻ ̷ ϴϱ ϳ. 纴 ¼? ؿ ȯ ̽ŵ? ó ȯڿ ȯ ̽ñ淡? 纴̸ ȯ Ǯ ٲ ٵ... 1 ȯڸ 5ε ° ƴ ϰ ڰ ۿ ... ڷ ϴ 뷯 ϼ.
|
80 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
纴 ȯ Ǯ ٲٰ? 纴 Ϸ翡 ϴ ? ֹ. ǻ س ϴµ ؾ ϰڽϱ
|
70 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
ٵ ϴ ˰ھ. Ǵ ô° ƿ ...;;
|
130 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
׳ ôµ ؼ ϰڽϱ Կִ 麸 ó.
|
40 |
![]() ![]() ![]() |
2024-11-22 |
||||||
|
|||||||||||
![]() |
![]() ȣī |
̱ ؼ ĪǾ ϰ ֱ
|
101 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
'ȯ Ǯ ٲ ʴ´' 'ȯڰ װ ִ' ˾Ƶ ͺ ⺻ ȵǾִµ
|
100 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
ƻ ȯǮ ؼ̳ ϰ ð, ϱ ú ϰ ΰ ⺻ Ǿ .
|
60 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
ó ʾҾ. ѱ ǻ翡 ӷ... ׳ ¥ . ٸ ǻ ִ° ...? ˰ھ ѵ
|
121 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ƴ̷ |
Ƕ Ͻðڳ ܱ ϴµ ܰ ϴٰ ġ Ű training ϰ ֽϴ. ŭ ߾ ѰŴ ׳ ƹ͵ " SGLT2 inhibitor ׳ ¼ ž̶ 索 SGLT2 ߵ!" µ ݹϴ°ſ. Metformin gold standard treatmentε ƹ͵ ̱ ȯڵ " ž ֳİ ݾƿ" UTI metformin adjuvant therapy ߵȴٴ Դϴ ȣī ڽ 忡 Ƕ°Ϳ ںν Ű , ƹ ͳ̶ Ա ʿ䰡 ٰ ؿ
|
250 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
̶ ϳ. ѱ 纴 Դµ 츮 ϴ ˰ھ. ѱ 亴 ˰? ̶ ġ.
|
120 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
ǰ Ŭп ٹϴ ôº 'ʴ ȯڸ ̰ ȯϰ ٸ ȯڱ ž' ѼҸ Ͻź ̶ ܾ ϴ° ʹ Inpatient 翬 Կȯڵ ° Ʈ̴ε ܷ ¦ϴ ѹ溴 Ʈ̴ Ƴ , ȯڻ, patient load ϰ ȵǰ Ʈ̴ε
|
101 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
ϳ ߰.
|
12 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ѵ |
ú ϴ ā줻ص ϴ
|
130 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
ȶϰ Ѿó ϼ~ evidence ؼ ũ Ŵٴº Ѿ óϳ . 9ؼ Ǵ µ ϴ° EBM̶ θ ϴ Ƶ̱Ⱑ 簡? ҰŸ ϳ ϼ ݰ ɷ ¦̴ٰ Ѱ 巯 ñ. ʰԶ ϸ Ҹ ϰҾ β Ͱ մϴ
|
60 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() o |
ϰ ġ.
|
11 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
/ ̽ ٰ ۿ . ʹ 翬ѰŶ... ٸ ʹ ؼ Գ^^ コɾε ٸ~ ؼ . ںν ̷ٶ ؾߵɰ Ƽ^*^
|
20 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ȣī |
Ortho ϴٰ psych̶... ...
|
10 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ص |
ǻ鳢ǽο̶... ȣ... ѵ?
|
130 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ںǰհ |
ٵ ǻ 9ϰ Ѱ ij Ȱ
|
110 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() Ⱘٷμڼ |
ǽ ˱ ߺýϴ
|
150 |
![]() ![]() ![]() |
2024-11-23 |
||||||
![]() |
![]() ũ |
մ
|
00 |
![]() ![]() ![]() |
2025-02-15 |
||||||
![]() |
̼Ǽ |
ǰ ð...ٵ ž ƴѰŰ
|
20 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() ʺ |
ð 츮 ǰ ప ķġ⸦ ߵ ϰ ö߽ϴ. ^^ 츮 ð . ֱ ̿ ó 索Ӿƴ϶ û ٴ ͼ ʿ ẕ̌ մϴ.
|
30 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
߰Ի |
߿~gliflozin̶ SGLT-2
|
00 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
dublemars |
ڵ Դµ ǻ δ 索 þư ξ.. 汤 ֱ ִµ ٰ ̰ Ծߵȴٴ
|
00 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() Ÿ |
Ʈ, ڵ, ƹũ Դµ
|
00 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() dublemars |
ھ 1̿? ݰ 2̿
|
00 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() Ÿ |
2 ̿. ν ´ ִġΰ ƿ. Ա ſ.
|
00 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() dublemars |
2 ν ´° ٰ ϴ..
|
10 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() Ÿ |
? ż ¾Ƶ ȴٰ ϴ
|
00 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
![]() dublemars |
ุ Ǹ ֻ ȴ° δǴϱ Դ° ..
|
00 |
![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
ϰѱװ |
索 簡 óִ° ۿ ̻״ ū ƴ϶ Ǵܵǰų, ٸȰϸ鼭 ذɹ ϱ óִ°Ű, ó ̻ ġ̶ ó Ӵ åӼ Ƹ ٸ Ҳ, ƴϸ ̰ Ծð ٷ ٽ ϴ
|
00 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
Ÿdz |
۸ Ѱ Ⱑ ؼ ѱ Ѵٴ°ǵ ??
|
00 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
質 |
µ ΰ ʿ ϱ..Ф
|
20 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
۷Ͻ |
ǻ翡 Ϸ翴
|
10 |
![]() ![]() ![]() ![]() |
2024-11-22 |
||||||
![]() |
̾ ٲµ ۿ(?) °Ŷ ¥ 4-5ųα ٵ ָ ¿ ̤
|
00 |
![]() ![]() ![]() ![]() |
2024-11-22 |
|||||||